Restar, Arjee http://orcid.org/0000-0003-2992-8198
Minalga, Brian J.
Quilantang, Ma. Irene
Adamson, Tyler
Dusic, Emerson
van der Merwe, Leigh-Ann
Millet, Greg
Rosadiño, Danvic
Laguing, Tanya
Lett, Elle
Everhart, Avery
Phillips, Gregory II
Janamnuaysook, Rena
Seekaew, Pich
Baker, Kellan
Ashley, Florence
Wickersham, Jeffrey
Wallace, Stephaun E.
Operario, Don
Gamarel, Kristi E.
Funding for this research was provided by:
National Institute of Mental Health (R25MH087217, R01MH115765, R01MH115765)
Fogarty International Center (R21TW012010)
Article History
Accepted: 7 March 2023
First Online: 4 April 2023
Declarations
:
: Rena Janamnuaysook has received research funding from Gilead Sciences, and speaker fees from ViiV Healthcare. Dr. Stephaun Wallace reports research funding from NIH/NIAID, Johnson and Johnson/Janssen, and Gilead. Dr. Leigh-Ann van der Merwe reports involvement as global community advisory group for Gilead’s Lenacapavir trial for transgender women. Arjee Restar, Brian J. Minalga, Ma Irene Quilantang, Tyler Adamson, Emerson Dusic, Greg Millet, Danvic Rosadiño, Tanya Laguing, Elle Lett, Avery Everhart, Gregory Phillips II, Pich Seekaew, Kellan Baker, Florence Ashley, Jeffrey Wickersham, Don Operario, and Kristi E. Gamarel, PhD, declare that they have no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.